RecruitingPhase 3NCT07219602
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Studying Dysbetalipoproteinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NewAmsterdam Pharma
- Intervention
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (20)
- Clinical Research Institute of Arizona, Sun City West, Arizona, United States
- Scripps Health - Whittier Diabetes Institute, La Jolla, California, United States
- UF Health Jackson, Jacksonville, Florida, United States
- East Coast Institute of Research LLC, Jacksonville, Florida, United States
- East Coast Institute of Research LLC, Lake City, Florida, United States
- Floridian Clinical Research, Miami Lakes, Florida, United States
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, United States
- MD Medical Research, Oxon Hill, Maryland, United States
- Jefferson City Medical Group, Jefferson City, Missouri, United States
- Montana Medical Research, Missoula, Montana, United States
- Inspira Health - Internal Medicine Associates, Bridgeton, New Jersey, United States
- Central New York Clinical Research, Manlius, New York, United States
- Velocity Clinical Research, Durham, North Carolina, United States
- Floridian Clinical Research, Greensboro, North Carolina, United States
- Centricity Research dba Lucas Research, Morehead City, North Carolina, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07219602 on ClinicalTrials.gov